KATP channel activators can partially suppress insulin secretion, are approved for the treatment of hyperinsulinemia, and would be useful to reduce the contribution of hyperinsulinemia to hyperphagia and obesity (Figure 1). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.